12,372 trials
Low Back Pain
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 70; 63; 67; 8 Participants
Migraine
Primary: Number of Participants Who Achieve Freedom From Headache — 4; 0 Participants
Alzheimer Disease
Primary: Primary Objective 1 Analysis 1: Diagnostic Performance of Individual Readers (NFT Score) — 91.5; 77.1; 89.4; 91.4 percentage of cases correctly identified
Hyperphosphatemia
Primary: Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms — 1.4; 0.6 mg/dL — p=0.01
Non-radiographic Spondyloarthritis
Primary: The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16 — 68; 70; 50…
Cystic Fibrosis
Primary: Safety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 56; 15 participants
Rheumatoid Arthritis (RA)
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 31.4; 71.6 percentage of participants — p=<0.001
Abortion in First Trimester
Primary: Worst Pain Measurement Via Numeric Rating Scale (NRS-11) — 8.0; 7.0; 7.5; 6.5 score on a scale — p=.20
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Coronary Artery Disease
Primary: Sensitivity and Specificity for Detection or Exclusion of Coronary Artery Disease (CAD) — 8.0; 33.7 percentage of participants — p=0.0896
Coronary Artery Disease
Primary: Sensitivity and Specificity of Lumason Enhanced Dobutamine Stress Echo (DSE) for Detection or Exclusion of Coronary Artery Disease (CAD) — 16.0; 37.9 percentage of…
Muscular Dystrophy, Duchenne · Muscular Dystrophies · Muscular Disorders, Atrophic
Primary: Change From Baseline in 6MWD at Week 48 — -60.67; -47.69 meters — p=0.213
Short Bowel Syndrome
Primary: Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET) — -2.92 Liter per week (L/Week)
Vaginal Infection
Primary: Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit — 31; 29; 43 Participants — p=0.030
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12 — 21.8; 58.6; 64.4 percentage of…